Clinical Trials Logo

Late Onset Alzheimer Disease clinical trials

View clinical trials related to Late Onset Alzheimer Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT04838301 Recruiting - Clinical trials for Neurodegenerative Diseases

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

REGEN-BRAIN©
Start date: August 15, 2023
Phase: Phase 2
Study type: Interventional

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

NCT ID: NCT03624842 No longer available - Clinical trials for Late Onset Alzheimer Disease

Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease

Start date: n/a
Phase:
Study type: Expanded Access

To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease who has no other disease-modifying treatment options.

NCT ID: NCT03349320 Completed - Clinical trials for Late Onset Alzheimer Disease

Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms

Start date: June 2009
Phase: N/A
Study type: Observational

Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits. Donepezil is a ChEI metabolized through the cytochrome P (CYP) 450, primarily by the 3A4 and 2D6 isoforms. The CYP2D6 gene presents polymorphisms that can alter its expression. The plasma therapeutic level ranges from 30 to 75 ng/mL, and 50% of acetylcholinesterase inhibition is achieved when the concentration reaches 15.6 ng/mL. An optimal plasma level is greater than 50 ng/mL. These polymorphisms may influence the individual's response to treatment with donepezil and the concentration of the drug in AD patients, without achieving the desired effect. However, most of the individuals are EM, i.e., the metabolism of the drug occurs according to the expected kinetics and is associated with the presence of one or two wild-type alleles. Objective: investigate the pattern of clinical response to donepezil in a group of patients with AD and AD with cerebrovascular disease (CVD) in relation to the plasmatic concentration of donepezil and polymorphisms of the CYP2D6 and apolipoprotein E (APOE) genes.

NCT ID: NCT01222351 Completed - Clinical trials for Late Onset Alzheimer Disease

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

Start date: December 2010
Phase: N/A
Study type: Interventional

The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline. The investigators will use baseline and longitudinal measurements of plasma amyloid beta-40 and amyloid beta-42 to investigate the risk of developing mild cognitive impairment and late onset Alzheimer's disease, as well as the rates of cognitive decline and Alzheimer's disease progression. The driving hypothesis of the study is that amyloid beta in the brain as measured by positron emission tomography positivity is associated with the onset of cognitive decline associated with late onset Alzheimer's disease.

NCT ID: NCT00064870 Recruiting - Alzheimer Disease Clinical Trials

Alzheimer's Disease Genetics Study

NCRAD
Start date: June 2002
Phase:
Study type: Observational

The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.